A retrospective study on titanium sensitivity: Patch test materials and manifestations

Niels P. J. de Graaf1,2 | Albert J. Feilzer3 | Cees J. Kleverlaan3 | Hetty Bontkes2,4 | Sue Gibbs1,2 | Thomas Rustemeyer1

1Department of Dermatology, VU University Medical Centre, Amsterdam, The Netherlands
2Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
3Department of Dental Materials Science, Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
4Unit Medical Immunology, Department of Clinical Chemistry, VU University Medical Centre, Amsterdam, The Netherlands

Correspondence
Professor Dr Thomas Rustemeyer,
Department of Dermato-Allergology and Occupational Dermatology, VU University Medical Centre Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Email: t.rustemeyer@vumc.nl

Funding information
Stichting voor de Technische Wetenschappen, Grant/Award Number: 13382

Background: Titanium is being increasingly used. Although it is considered to be a non-allergenic material, allergic reactions to it have been reported. Titanium dioxide has been found to be an unreliable patch test material. Few studies to date have profiled titanium allergy, and it therefore remains difficult to distinguish its manifestations.

Objectives: To evaluate alternatives for titanium dioxide as a patch test preparation, and to profile titanium reactions and manifestations.

Methods: A retrospective chart review was conducted with 458 patients who underwent patch testing with at least 1 of 5 different titanium salts.

Results: At least 1 positive result was noted in 5.7% of the patients. The frequency of positive results for the tested salts ranged from 0.9% to 7.9%. Titanium(IV) oxalate hydrate had the highest yield and titanium dioxide the lowest. Erythema, dermatitis and local swelling were the most common objective complaints. In 16 (61.5%) patients, the test result had partial or full clinical relevance.

Conclusions: No titanium-specific risk factors and clinical picture could be identified. Titanium dioxide is not adequately sensitive for identifying titanium allergy. The titanium salts seem to be possible superior patch test preparations, but appear to be unsuitable if used singly. The patient’s medical history and clinical picture remain crucial in the diagnostic work-up.

KEYWORDS
contact allergy, dermatitis, implants, medical device, patch test, titanium

INTRODUCTION

Titanium (Ti) is a lustrous transition metal that is widely used as an implant material in medicine and dentistry, and, in its oxide form, as a white pigment in personal care products and food. It is often chosen as an implant material, owing to its corrosion resistance and good biocompatibility.1,2 Many new Ti implant applications are being developed, and, because the age of the western population is increasing, human exposure to Ti is also increasing.3,4

Although Ti is generally believed to be “hypo-allergenic”, numerous articles have been published describing allergic reactions to Ti.5–7 The prevalence of Ti allergy is not known, but is estimated to be very low. Reports on Ti allergy have been summarized by Wood et al and Fage et al.8,9 They describe adverse effects of Ti, namely, local and systemic symptoms such as local eczema in areas over an implant, pruritus, pain, chronic fatigue syndrome, and neurological symptoms.

Clinical experience with dental and orthopaedic implant patients suggests that Ti allergy occurs more often than patch tests indicate.10–12 The most widely used patch test preparation is Ti dioxide (TiO₂), but it rarely confirms clinical suspicion. This might be explained by its poor solubility, resulting in inadequate skin penetration.6,7 Other Ti salts, such as Ti(IV) chloride, Ti(II) sulfate, Ti(IV) diethanedioate, Ti salicylate, Ti(IV) tetrahydroxide, calcium tinate, Ti(III) nitride, and Ti(IV) oxalate hydrate, have been suggested, but only a few studies have actually examined the use of these salts.9,13
In our clinic, during the past 10 years, different Ti test salts have been applied to evaluate possible sensitization to Ti. In this study, our objective was to report the frequency of positive patch test reactions to Ti dioxide and its alternatives applied in our clinic. In addition, this article describes the clinical presentation of Ti-allergic patients in our clinic.

2 | MATERIALS AND METHODS

After obtaining approval from our institutional review board, we performed a retrospective chart review on patients who underwent patch testing with ≥1 Ti test salts at the Allergy Unit of the Department of Dermatology at the VU University Medical Centre between January 1, 2004 and January 1, 2017. The Ti test salts that were used, the rationale for performing patch tests and the test results were recorded for all patients. For those with at least 1 positive patch test result, additional data were collected on sex, age, symptoms, implanted devices, clinical diagnoses, and relevance of the positive result.

All patients were tested with ≥1 Ti salts depending on the date of referral and the Ti salts used at that time (Table 1). The test materials used were TiO₂, Ti(IV) oxalate hydrate, Ti(IV) isopropoxide, Ti lactate, and Ti citrate. Patch testing was performed with Van der Bend chambers (van der Bend, Brielle, The Netherlands). Patch test chambers were removed from the backs of the patients after 48 hours of exposure, and readings were performed on day (D) 2, D3, and D7. Positive reactions rated as +, ++ or +++ in accordance with the ICDRG/ESCD reading criteria were regarded as allergic, whereas doubtful reactions (?+) were not. The relevance of the positive reactions was assessed. An allergen was considered to be clinically relevant if: (1) the existence of exposure could be established, and (2) the patient’s complaints could be explained (completely or partially) with regard to that exposure. The relevance was categorized as complete, partial, past, no and unknown relevance. Evaluations were performed by an experienced dermatologist.

A 2-tailed Fisher’s exact test was used, as appropriate, to compare proportions of positive reactions to the Ti compounds in patients suspected of having Ti allergy with those in the control group. The significance level for all analyses was P < .05.

3 | RESULTS

A total of 458 patients were tested with ≥1 Ti salts (see Table S1 for combinations and numbers). At least 1 positive result was noted in 5.7% of patients (n = 26). The results of patch testing with the Ti salts are shown in Table 2. Most positive reactions were seen to Ti(IV) oxalate hydrate (7.9%; 216 tested). This was followed by Ti lactate (4.4%; 45 tested), Ti(IV) isopropoxide (2.9%, 272 tested), Ti citrate (2.2%; 45 tested), and TiO₂ (0.9%; 329 tested). However, it should be noted that the patient groups for Ti citrate and Ti lactate were small as compared with those for the other salts.

Patients could be divided into three groups: group 1 (n = 248) comprised patients suspected of having Ti allergy; group 2 (n = 163) comprised patients suspected of having a metal allergy other than to Ti; and group 3 (n = 47) comprised patients who were not exposed to Ti-containing medical devices and did not have a specific history of Ti allergy, henceforth called the control group. In group 1, 22 patients showed positive test reactions (8.9%). In groups 2 and 3, 2 patients showed positive reactions (1.2% and 4.3%, respectively) (Table 3). The number of positive Ti reactions in patients suspected of having Ti allergy (group 1) was not statistically different from that in the control group (group 3) (P = .39). Exclusion of patients with positive patch test reactions to other metals did not influence the statistics.

Of the 26 positive patients, 23 reacted to only one Ti salt; the remaining 3 reacted to two Ti salts. Nickel and cobalt were the most frequent co-reactants (both 19.2%). Notably, no Ti salt was found that was universally positive in patients who had positive test reactions. The mean age of the positive subjects was 55.2 years (range 20-80 years); 53.8% were female. Most of the Ti-positive patients had local symptoms such as pain, erythema, and dermatitis, but other symptoms, such as pruritus, impaired wound healing, and swelling, were also seen. Fifteen of the 26 (57.7%) had a proven Ti-containing implant or reconstructive material. Most were orthopaedic and surgical (n = 10) or dental (n = 3), but 1 patient had a neurostimulator and another had an implanted insulin pump. In 16 of 26 (61.5%) positive patients, complete or partial clinical relevance of the positive result

### Table 1

| Allergen               | Formula                                      | Since year: | Concentration and vehicle | Manufacturer                                      |
|------------------------|----------------------------------------------|-------------|---------------------------|--------------------------------------------------|
| Ti dioxide             | TiO₂                                         | 2004        | “as is”                   | Material science laboratory ACTA                  |
| Ti(IV) isopropoxide    | [Ti(OC(H₃)₂)₄]                               | 2009        | 10 ppm pet., 100 ppm pet., 500 ppm pet., 0.10% pet., 0.20% pet., 1% pet., 5% pet., 10% pet., 20% pet. | Material science laboratory ACTA                  |
| Ti(IV) oxalate hydrate | Ti(C₂O₄)H₂•H₂O                               | 2012        | 5% pet.                   | Chemotechnique Diagnostics                       |
| Ti lactate             | C₁₂H₂₀O₁₂Ti                                  | 2014        | 0.04% pet., 0.08% pet., 0.16% pet., 0.24% pet. | SmartPractice Allergen Bank                      |
| Ti citrate             | C₁₂H₁₀O₁₄Ti                                  | 2014        | 0.04% pet., 0.08% pet., 0.16% pet., 0.32% pet. | SmartPractice Allergen Bank                      |

### Table 2

| Tested for titanium sensitization | N   | Positive n | %   |
|-----------------------------------|-----|------------|-----|
| Titanium salt                     |     |            |     |
| Ti(IV) oxalate hydrate            | 216 | 17         | 7.87|
| Ti(IV) isopropoxide               | 272 | 8          | 2.94|
| Ti citrate                        | 45  | 1          | 2.22|
| Ti lactate                        | 45  | 2          | 4.44|
| Ti dioxide                        | 329 | 3          | 0.91|
TABLE 3  Patch test results per group and salt 2004 to 2016

| Salt                               | N   | Positive n | %  |
|------------------------------------|-----|------------|----|
| Group 1 (suspected titanium allergy)|     |            |    |
| Ti(IV) oxalate hydrate             | 248 | 22         | 8.87|
| Ti(IV) isopropoxide                | 174 | 15         | 8.62|
| Ti dioxide                         | 224 | 8          | 3.57|
| 100 ppm                            | 224 | 1          | 0.44|
| 1%                                 | 224 | 4          | 1.78|
| 5%                                 | 224 | 1          | 0.46|
| 10%                                | 224 | 2          | 0.44|
| Ti citrate                         | 37  | 1          | 2.70|
| 0.16%                              | 37  | 1          | 2.70|
| 0.32%                              | 37  | 1          | 2.70|
| Ti lactate                         | 37  | 2          | 5.41|
| 0.16%                              | 37  | 2          | 5.41|
| Ti dioxide                         | 139 | 1          | 0.72|
| Group 2 (suspected metal allergy)  |     |            |    |
| Ti(IV) oxalate hydrate             | 163 | 2          | 1.23|
| Ti(IV) isopropoxide                | 4   | 0          | 0   |
| Ti dioxide                         | 159 | 2          | 1.26|
| Group 3 (control group)            |     |            |    |
| Ti(IV) oxalate hydrate             | 47  | 2          | 4.26|
| Ti(IV) isopropoxide                | 38  | 2          | 5.26|
| Ti citrate                         | 44  | 0          | 0   |
| Ti lactate                         | 8   | 0          | 0   |
| Ti dioxide                         | 31  | 0          | 0   |

was determined. The demographic characteristics of the patients are summarized in Tables 4 and 5.

4 | DISCUSSION

We performed a retrospective study on all patients patch tested with Ti salts in our hospital. A key finding is that the frequency of Ti sensitivity in this large group of patients was 5.7%. This frequency was higher than the sensitivity found in a study by Sicilia et al, which was 0.6%, and that found in a study by Lhotka et al, which was 2%. However, in these studies, only TiO₂ was used, which might account for the difference in sensitization occurrence from that in our study. A study in Lithuania reported no positive patch test reaction to any of the 5 Ti salts present in their metal series. However, only a relatively small number of patients were tested. There are currently no reports in which a panel of Ti salts has been used on a large patch test population.

We tested a highly selected population; therefore, the high frequency of Ti sensitization that we found cannot be extrapolated to the general population. In the group of patients suspected of having Ti allergy, an even higher frequency of 8.9% was observed. Interestingly, this frequency was not statistically different from the frequency found in the control group (P = .39). This may be explained by the small sample size of the control group and the relatively low numbers of positive reactions within both groups. Also, the possible referral bias resulting from the selection of patients on the basis of their clinical history has to be taken into account. The potential differences in accuracy of the Ti salts should also be considered. The retrospective nature of this study makes it difficult to address these problems.

TiO₂ is the most common patch test salt. It is an inert and highly insoluble material. Fage et al reviewed several studies on the penetration of TiO₂, and did not find any studies that showed TiO₂ penetration through the epidermis and into viable skin layers. Because of these characteristics, there is a high probability of false-negative test results, regardless of the test concentration used. Nevertheless, in a summary of TiO₂ patch testing reports, Wood et al described 21 patients with positive reactions. Unfortunately, no information on clinical relevance was provided. Our patch tests also showed some positive reactions to TiO₂ (n = 3, 0.9%) in a large group of patients. In 1 patient (no. 22) with generalized eczema, TiO₂ was tested because her eczema was exacerbated on the locations on which a Ti-containing sunscreen was applied. The patient reacted positively to multiple possible components of sunscreens, eg, cosmetic preservatives, wool alcohol, fragrance mix, benzophenone, and Ti. Although partial relevance was identified, the role of Ti hypersensitivity can be considered to be insignificant in this case. No other reports of allergic reactions to Ti in sunscreens are known, and several studies have shown that TiO₂ in sunscreens does not penetrate into the viable epidermis. In 2 patients in group 2, positive reactions to TiO₂ were found. In one patient (no. 10), the positive result was of no relevance for his dyshidrotic hand eczema, as no source of Ti contact could be found. The other patient (no. 15) with local dermatitis on a tattoo location had negative test results with all of the tattoo ink components. No source of Ti contact could be determined, and the result was therefore of no relevance. These results support the questionable relevance of positive TiO₂ results. This is emphasized by the lack of studies in which a positive patch test result is supported by a positive in vitro test. This study confirms, in a large population, that TiO₂ as a patch test preparation is of no value in clinical practice.

The use of Ti(IV) oxalate hydrate [Ti₃O₆(H₂O)₄] as a patch test salt was first described in 1975. Only recently has it been as an alternative to TiO₂ in clinical practice. Chemotechnique Diagnostics initially labelled it as Ti(III) oxalate decahydrate; later, this was corrected to Ti(IV) oxalate hydrate. The test material itself was not changed. In our study, it was, notably, the highest-scoring Ti salt, with positive reactions in 17 subjects (7.9%). Several cases have shown that Ti oxalate can show Ti sensitivity in TiO₂-negative patients. This is similar to our experience, in which 8 patients who reacted positively to Ti oxalate were also tested with TiO₂; none of the tests gave a positive result. However, the difference in frequency of positive Ti oxalate reactions between patients suspected of having Ti allergy and the control group was non-significant (P = .74). As outlined above, this lack of significance may be attributable to unequal group sizes (n = 174 vs n = 38) and the retrospective nature of this study. This made statistical analysis for comparison of the groups difficult.

Nevertheless, positive reactions in the control group, in which sensitization to Ti is highly unlikely, highlight the possibility of false-positive reactions. This is emphasized by the fact that 13 of the 17 positive subjects were tested with 2 Ti oxalate hydrate patches, but no concomitant reaction was seen in 8 (61.5%) of these subjects. Ti oxalate may be irritant in nature, owing to the low pH of 2.0-3.0
when it is exposed to air. Arguably, this may not be the case when it is dissolved in petrolatum. A study by Bernard et al found only negative results in 30 control subjects who were patch tested with Ti oxalate, including in atopics.23 The authors therefore considered irritancy to be unlikely. To our knowledge, no large studies investigating the performance of Ti oxalate as a patch test salt exist. The present study shows that it is a superior salt for patch testing and can be of value in clinical practice. This is emphasized by the finding of complete or partial relevance in 73.3% of the Ti(IV) oxalate hydrate-positive subjects in group 1. However, the significance of a positive reaction to Ti(IV) oxalate hydrate remains debatable, and has to be extensively examined on a case-by-case basis. Thus, results obtained with Ti oxalate should be interpreted with care until results from larger groups of tested patients are available for comparison.

Given the small test groups for Ti citrate and Ti lactate, no estimation can be made about their value in clinical practice. However, the good water solubility of Ti lactate and its ability to produce positive

### TABLE 4  Patch test results and characteristics of titanium-positive patients

| Patient | Age (years)/sex | Patch test | Clinical presentation | Ti implant(s) | Clinical relevance |
|---------|-----------------|------------|----------------------|---------------|-------------------|
| 1^a     | 66/F            | NT         | + (D3)               | (D3, D7)      | Pr                |
| 2^a     | 54/M            | + (D3)     | NT                   |               | Neurostimulator    |
| 3^a     | 74/F            | + (D3)     | NT                   | (D3)          | Orthopaedic Complete |
| 4^a     | 44/F            | + (D3)     | NT                   | (D3)          | Orthopaedic Partial |
| 5^a     | 47/M            | + (D3)     | NT                   |               | Insulin pump Partial |
| 6^a     | 66/F            | + (D7)     | NT                   | (D3)          | Dental Complete    |
| 7^a     | 80/M            | + (D3)     | NT                   |               | BS                |
| 8^a     | 28/F            | + (D3, D7) | NT                   |               | Orthopaedic Partial |
| 9^b     | 64/F            | + (D3)     | NT                   |               | No                |
| 10^a    | 27/M            | + (72 h)   | NT                   |               | No                |
| 11^a    | 57/F            | + (D3)     | NT                   |               | Orthopaedic Past   |
| 12^a    | 57/F            | + (D2, D3) | NT                   |               | Fa, P             |
| 13^b    | 54/M            | + (D3, D7) | NT                   |               | Unknown            |
| 14^b    | 58/F            | + (D7)     | NT                   |               | Partial            |
| 15^c    | 50/F            | + (72 h)   | NT                   |               | No                |
| 16^a    | 75/M            | + (D3)     | NT                   |               | Orthopaedic Partial |
| 17^a    | 20/F            | + (D7)     | NT                   |               | Fa, IWH Surgical   |
| 18^a    | 58/F            | + (D3)     | NT                   |               | Orthopaedic Partial |
| 19^a    | 60/M            | + (D3)     | NT                   |               | S, P               |
| 20^a    | 63/F            | + (D3)     | NT                   |               | Orthopaedic Partial |
| 21^a    | 64/M            | + (D3)     | NT                   |               | Partial            |
| 22^a    | 48/F            | + (72 h)   | NT                   |               | Partial            |
| 23^a    | 62/M            | + (D3)     | NT                   |               | Partial            |
| 24^a    | 40/M            | + (D3)     | NT                   |               | Unknown            |
| 25^a    | 63/M            | + (D3)     | + (72 h)             |               | Dental             |
| 26^a    | 57/M            | + (D3)     | + (D3)               |               | Dental             |

Abbreviations: BS, burning sensation; De, dermatitis overlying the implant; DE, dermatitis elsewhere; ES, excessive saliva; ET, erythema; F, female; Fa, fatigue; IWH, impaired wound healing; LE, lichenoid eruption; M, male; NT, not tested; P, pain; PI, peri-implantitis; Pr, pruritis; S, swelling.

^a Group 1.
^b Group 3.
^c Group 2.

### TABLE 5  Characteristics of 26 patients with a positive patch test reaction to titanium

| Characteristic                          | Overall |
|----------------------------------------|---------|
| Age (years)                            | 55.2    |
| Range                                  | 20–74   |
| Female, n (%)                          | 14 (53.8) |
| Clinical relevance, n (%)              | 14 (53.8) |
| No                                     | 5 (19.2) |
| Complete                               | 2 (7.7)  |
| Partial                                | 14 (53.8) |
| Unknown                                | 4 (15.4) |
| Past                                   | 1 (3.8)  |
| Titanium implant                       | 15 (57.7) |
| Dental                                 | 3 (20.0) |
| Orthopaedic/surgical                   | 10 (66.7) |
| Other                                  | 2 (13.3) |
reactions makes it an interesting patch test salt for further investigation. This is emphasized by Basketter et al, who described 3 TiO2-negative patients who had positive reactions to a complex Ti lactate.25 Investigating Ti isopropoxide could also be interesting, as it gave positive reactions in 8 patients. However, these results are enigmatic; even though Ti oxalate and Ti isopropoxide were simultaneously tested in 213 patients (including 20 of the 26 positive patients), there were only 2 concomitant reactions. From our data, no patient-specific characteristics can be identified that could explain this. It may be interpreted as being attributable to false-positive reactions to either of the materials. This interpretation is reinforced by the lack of multiple reactions to different Ti isopropoxide concentrations per patient, and the lack of reactions to higher concentrations in these patients. This might be the consequence of an inhomogeneous distribution of the allergen in the patch test vehicle. Therefore, no preferable concentration of Ti isopropoxide could be determined. Furthermore, no salt was capable of diagnosing all sensitized patients. Although it can be expected that testing with the expanded Ti series will enhance the detection of relevant positive reactions, the accuracy of these test salts can be questioned. Unfortunately, assessing the accuracy of each of these salts is not within the scope of this study. Additional prospective studies should evaluate the diagnostic accuracy, taking into account the lack of a gold reference standard.

Alternative diagnostic tools such as in vitro blood tests (lymphocyte transformation test [LTT] and memory lymphocyte immunostimulation assay) are available but have not yet been fully accepted as comparable alternative diagnostic tests. In our experience, the LTT is more appropriate for diagnosing sensitization in people who are sensitized and currently exposed, and less appropriate for people who are sensitized and not currently exposed. This topic needs more study. Therefore, from this study we conclude that, although the delayed positive reactions (mainly on D3) are in favour of a true allergic reaction, it cannot be confirmed whether Ti is a true sensitizer, whether the recorded positive results underestimate sensitization, or how the specific symptoms of a Ti sensitization are expressed. If Ti is a sensitizer, it is probably a weak one, and the fact that the majority of our patients showed mostly + reactions supports this notion. However, the test concentration, salt preparation and choice of vehicle may still need optimization. Studies on the immunological effects of Ti exposure have not yet led to a consensus on its sensitizing capabilities. A study by Lalor et al showed T lymphocytes and macrophages in the absence of B lymphocytes in the tissue of total hip revision surgery patients, suggesting Ti allergy.10 In contrast, Park et al26 using a local lymph node assay, found that TiO2 was not a dermal sensitizer.

In both the literature and this study, Ti allergy typically occurred in implant patients suffering from postoperative complaints. We identified erythema, dermatitis (overlying the implant or elsewhere), and local swelling. Patients also reported pruritus, a burning sensation, and pain. These results are in line with those of previous studies. However, the relationship between implant-related complaints and allergy remains much debated. Determining the relevance of a positive test reaction in these patients is a challenge. Although we describe relevance in 61.5%, it was difficult to determine whether a positive reaction was putatively responsible for the clinical complaints. Given the multifactorial background of the above-mentioned complaints, other factors, such as aseptic loosening, osteolysis and infection, may also play a significant role.27 Moreover, possible sensitization to other components within the implant makes it complex to determine whether Ti is the primary cause, is an aggravating factor, or is not involved at all in the pathogenesis of the clinical complaints. It was sometimes difficult, and often impossible, to retrospectively determine the relative influences of all these different factors; hence the high amount of partial relevance in our study. Sufficient information on previous diagnostic outcomes and implanted materials is therefore crucial. Fortunately, the composition of dental implants and reconstructive materials can be determined by taking microsamples.28 This method also detects possible trace metals that are not listed by the manufacturer or registered by the clinician, but may be involved in the clinical manifestation. In addition, a study by Bernard et al showed the presence of many impurities in commercialized Ti patch test samples.23 Even though there is no proof that the level of impurities in the patch test Ti salts is sufficient to cause elicitation, it highlights the importance of testing all implanted materials and investigating the existence of allergenic exposures.

Our study had several limitations. It was a retrospective study, so it was difficult to assign relevance, designate a control group, and rule out the possibility of referral bias occurring. In addition, not all of the patients were screened with the same salts, as the Ti series has expanded over the last 10 years. However, our study is the first to test a panel of Ti salts on a large patch test population. Future prospective studies could avoid these limitations, and further assess the accuracy of Ti patch test salts.

In conclusion, the frequency of Ti sensitivity in our patch test population was 5.7%. The alternative Ti patch test salts evaluated in this study enhance the diagnostic work-up, as they are possibly superior to TiO2 as test salts for patch testing. However, a single Ti salt cannot be used as a patch test preparation, as patient-specific responses occur to different salts, their accuracy in diagnosing Ti sensitization is mostly unknown, and determining the relevance of a positive result is still challenging. This illustrates the problems that clinicians face in evaluating Ti allergy, indicating that large-scale prospective studies are necessary to develop new patch test salts and improve alternative diagnostic tools such as the LTT. It remains important to diagnose on a case-by-case basis, duly taking the medical history and the clinical picture into account.

Conflict of interest
The authors declare no potential conflict of interests.

ORCID

Sue Gibbs ORCID: http://orcid.org/0000-0002-3446-6138

REFERENCES

1. Saini M, Singh Y, Arora P, Arora V, Jain K. Implant biomaterials: a comprehensive review. World J Clin Cases. 2015;3:52-57.
2. Messer W. Dental materials: biocompatibility. In: Buschow KHJ, ed. Encyclopedia of Materials: Science and Technology. Amsterdam, The Netherlands: Elsevier; 2002:1-10.
3. Akagawa Y, Abe Y. Titanium: the ultimate solution or an evolutionary step? Int J Prosthodont. 2003;16(suppl):28-29. discussion 47-51.
4. Elias CN, Lima JHC, Valiev R, Meyers MA. Biomedical applications of titanium and its alloys. JOM. 2008;60:46-49.
5. Matthew I, Frame JW. Allergic responses to titanium. J Oral Maxillofac Surg. 1998;56:1466-1467.
6. Muller K, Valentine-Thom E. Hypersensitivity to titanium: clinical and laboratory evidence. Neuroendocrinol Lett. 2006;27(suppl 1):31-35.
7. Sicília A, Cuesta S, Coma G, et al. Titanium allergy in dental implant patients: a clinical study on 1500 consecutive patients. Clin Oral Implants Res. 2008;19:823-835.
8. Fage SW, Muris J, Jakobsen SS, Thyssen JP. Titanium: a review on exposure, release, penetration, allergy, epidemiology, and clinical reactivity. Contact Dermatitis. 2016;74:323-345.
9. Wood MM, Warshaw EM. Hypersensitivity reactions to titanium: diagnosis and management. Dermatitis. 2015;26:7-25.
10. Lalor PA, Revell PA, Gray AB, Wright S, Ralston GT, Freeman MA. Sensitivity to titanium. A cause of implant failure? J Bone Joint Surg Br. 1991;73:25-28.
11. Thomas P, Bandl WD, Maier S, Summer B, Przybilla B. Hypersensitivity to titanium osteosynthesis with impaired fracture healing, eczema, and T-cell hyperresponsiveness in vitro: case report and review of the literature. Contact Dermatitis. 2004;55:199-202.
12. van Opstal N, Verheyden F. Revision of a tibial baseplate using a customized oxinium component in a case of suspected metal allergy. A case report. Acta Orthop Belg. 2011;77:691-695.
13. Chemotechnique Diagnostics. Titanium Patch Test Haptens [Internet]. 2017. https://www.chemotechnique.se/products/products/
14. Johansen JD, Aalto-Korte K, Agner T, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. Contact Dermatitis. 2015;73:195–221.
15. Lachapelle J-M, Maibach HI. Clinical Relevance of Patch Test Reactions. Patch Testing and Prick Testing–A Practical Guide Official Publication of the ICDRG. Berlin, Germany: Springer-Verlag; 2009:113-120.
16. Lhotka CG, Szekeres T, Fritzer-Szekeres M, et al. Are allergic reactions to skin clips associated with delayed wound healing? Am J Surg. 1998;176:320-323.
17. Linauskiene K, Malinauskiene L, Blaziene A. Metals are important contact sensitizers: an experience from Lithuania. Biomed Res Int. 2017;2017:3964045.
18. Filipe P, Silva JN, Silva R, et al. Stratum corneum is an effective barrier to TiO2 and ZnO nanoparticle percutaneous absorption. Skin Pharmacol Physiol. 2009;22:266-275.
19. Popov AP, Lademann J, Priezzhev AV, Mylyla R. Effect of size of TiO2 nanoparticles embedded into stratum corneum on ultraviolet-A and ultraviolet-B sun-blocking properties of the skin. J Biomed Opt. 2005;10:064037.
20. Elkes MW, Wilson JN, Scales JT, Kemp HB. Incidence of metal sensitivity in patients with total joint replacements. Br Med J. 1975;4:376-378.
21. Shaw T, Simpson B, Wilson B, Oostman H, Rainey D, Storrs F. True photoallergy to sunscreens is rare despite popular belief. Dermatitis. 2010;21:185-198.
22. Vermes C, Kuzsner J, Bardos T, Than P. Prospective analysis of human leukocyte functional tests reveals metal sensitivity in patients with hip implant. J Orthop Surg Res. 2013;8:12.
23. Bernard S, Baech M, Tennstedt D, Hauflord V, Dekeuleneer V. Chromate or titanium allergy—the role of impurities? Contact Dermatitis. 2013;68:191-192.
24. Olsen KC, Barnes P, Morton K, Norris P. A patch test-positive titanium hypersensitivity reaction. Dermatitis. 2016;27:229-230.
25. Basketter DA, Whittle E, Monk B. Possible allergy to complex titanium salt. Contact Dermatitis. 2000;42:310-311.
26. Park YH, Jeong SH, Yi SM, et al. Analysis for the potential of polystyrene and TiO2 nanoparticles to induce skin irritation, phototoxicity, and sensitization. Toxicol In Vitro. 2011;25:1863-1869.
27. Ferrata P, Carta S, Fortina M, Sciolo D, Riva A, Di Giacinto S. Painful hip arthropathy: definition. Clin Cases Miner Bone Metab. 2011;8:19-22.
28. Muris J, Feilzer AJ. Micro analysis of metals in dental restorations as part of a diagnostic approach in metal allergies. Neuroendocrinol Lett. 2006;27(suppl 1):49-52.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: de Graaf NPJ, Feilzer AJ, Kleverlaan CJ, Bontkes H, Gibbs S, Rustemeyer T. A retrospective study on titanium sensitivity: Patch test materials and manifestations. Contact Dermatitis. 2018;79:85–90. https://doi.org/10.1111/cod.13010